Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients.
OBJECTIVE
Secondary analysis of the Hemodialysis Study showed that serum beta(2)-microglobulin levels predicted all-cause mortality and that high-flux dialysis was associated with decreased cardiac deaths in hemodialysis patients. This study examined the association of serum beta(2)-microglobulin levels and dialyzer beta(2)-microglobulin kinetics with the two most common causes of deaths: Cardiac and infectious diseases. Cox regression analyses were performed to relate cardiac or infectious deaths to cumulative mean follow-up predialysis serum beta(2)-microglobulin levels while controlling for baseline demographics, comorbidity, residual kidney function, and dialysis-related variables.


RESULTS
The cohort of 1813 patients experienced 180 infectious deaths and 315 cardiac deaths. The adjusted hazard ratio for infectious death was 1.21 (95% confidence interval 1.07 to 1.37) per 10-mg/L increase in beta(2)-microglobulin. This association was independent of the prestudy years on dialysis. In contrast, the association between serum beta(2)-microglobulin level and cardiac death was not statistically significant. In similar regression models, higher cumulative mean Kt/V of beta(2)-microglobulin was not significantly associated with either infectious or cardiac mortality in the full cohort but exhibited trends suggesting an association with lower infectious mortality (relative risk 0.93; 95% confidence interval 0.86 to 1.01, for each 0.1-U increase in beta(2)-microglobulin Kt/V) and lower cardiac mortality (relative risk 0.93; 95% confidence interval 0.87 to 1.00) in the subgroup with >3.7 prestudy years of dialysis.


CONCLUSIONS
These results generally support the notion that middle molecules are associated with systemic toxicity and that their accumulation predisposes dialysis patients to infectious deaths, independent of the duration of maintenance dialysis.
Medical Service, University of Utah, Salt Lake City, UT 84112, USA. alfred.cheung@hsc.utah.edu
Alfred K
AK
Cheung
Tom
T
Greene
John K
JK
Leypoldt
Guofen
G
Yan
Michael
M
Allon
James
J
Delmez
Andrew S
AS
Levey
Nathan W
NW
Levin
Michael V
MV
Rocco
Gerald
G
Schulman
Garabed
G
Eknoyan
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006331:Heart Diseases / Q000097:blood / Q000401:mortality*; D006801:Humans; D007239:Infections / Q000097:blood / Q000401:mortality*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000401:mortality* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D006435:Renal Dialysis / Q000401:mortality*; D014511:Uremia / Q000097:blood / Q000401:mortality / Q000628:therapy; D001613:beta 2-Microglobulin / Q000097:blood*
D015415:Biomarkers; D001613:beta 2-Microglobulin